Detection of myocardial disorders by magnetic resonance spectroscopy

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue SUPPL. 2, 2008, Pages

  Hudsmith, Lucy E ^a,b   Neubauer, Stefan ^a,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CARNITINE; CREATINE; CREATINE PHOSPHATE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOLINIUM PENTETATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; PHOSPHORUS 31; TRACER;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL COMPOSITION; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; ENERGY TRANSFER; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE METABOLISM; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MYOCARDIAL DISEASE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PHOSPHATE METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; SIGNAL TRANSDUCTION; SODIUM NUCLEAR MAGNETIC RESONANCE; TREATMENT RESPONSE; VALVULAR HEART DISEASE;

CARDIOMYOPATHIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIUM; PHOSPHORUS;

EID: 48349135679     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1158     Document Type: Article

References (43)

1. Garlick PB eta al. (1977) Phosphorus NMR studies on perfused heart. Biochem Biophys Res Commun 74: 1256-1262
2. Ingwall JS (1982) Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242: H729-H744
3. Neubauer S (2003) Cardiac magnetic resonance spectroscopy. In Cardiovascular Magnetic Resonance: Established and Emerging Applications 39-60 (Eds Lardo AC et al.). London: Taylor and Francis Group
4. Bottomley PA et al (1996) Human cardiac high-energy phosphate metabolite concentrations by 1D-resolved NMR spectroscopy. Magn Reson Med 35: 664-670
5. Bottomley PA et al. (1990) Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance. Magn Reson Med 14: 425-434
6. Bottomley PA (1994) MR spectroscopy of the human heart: The status and the challenges. Radiology 191: 593-612
7. Pohmann R and von Kienlin M (2001) Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn Reson Med 45: 817-826
8. Lamb HJ et al. (1996) Reproducibility of human cardiac 31P-NMR spectroscopy. NMR Biomed 9: 217-227
9. Bessman SP and Geiger PJ (1981) Transport of energy in muscle: The phosphorylcreatine shuttle. Science 211: 448-452
10. Bottomley PA and Weiss RG (2001) Noninvasive localized MR quantification of creatine kinase metabolites in normal and infarcted canine myocardium. Radiology 219: 411-418
11. Kohler SJ et al. (1991) Analysis of 23Na NMR spectra from isolated perfused hearts. Magn Reson Med 18: 15-27
12. Horn M et al. (2001) Detection of myocardial viability based on measurement of sodium content: A (23)Na-NMR study. Magn Reson Med 45: 756-764
13. Sandstede JJ et al. (2001) Assessment of myocardial infarction in humans with (23)Na MR imaging: Comparison with cine MR imaging and delayed contrast enhancement. Radiology 221: 222-228
14. Okada M et al. (1998) Influence of aging or left ventricular hypertrophy on the human heart: Contents of phosphorus metabolites measured by 31P MRS. Magn Reson Med 39: 772-782
15. Conway MA et al. (1988) Cardiac metabolism during exercise measured by magnetic resonance spectroscopy. Lancet 2: 692
16. Pluim BM et al. (1998) Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation 97: 666-672
17. Neubauer S (2007) The failing heart?an engine out of fuel. N Engl J Med 356: 1140-1151
18. Neubauer S et al. (1995) Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 16 (Suppl): S115-S118
19. Neubauer S et al. (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86: 1810-1818
20. Neubauer S et al. (1997) Myocardial phosphocreatineto-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96: 2190-2196
21. Ashrafian H et al. (2003) Hypertrophic cardiomyopathy: A paradigm for myocardial energy depletion. Trends Genet 19: 263-268
22. Maron BJ (2002) Hypertrophic cardiomyopathy: A systematic review. JAMA 287: 1308-1320
23. Crilley JG et al. (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41 1776-1782
24. Jung WI et al. (1998) 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97: 2536-2542
25. Crilley JG et al. (2000) Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol 36: 1953-1958
26. Schocke MF et al. (2004) Cardiac phosphorus-31 twodimensional chemical shift imaging in patients with hereditary hemochromatosis. Magn Reson Imaging 22: 515-521
27. Schocke MF et al. (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors improve myocardial high-energy phosphate metabolism in men. J Cardiovasc Magn Reson 5: 595-602
28. Lamb HJ et al. (1999) Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99: 2261-2267
29. Clarke K et al. (1987) Temporal relation between energy metabolism and myocardial function during ischemia and reperfusion. Am J Physiol 253: H412-H421
30. Weiss RG et al. (1990) Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 323: 1593-1600
31. Yabe T et al. (1995) Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 92: 15-23
32. Buchthal SD et al. (2000) Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 342: 829-835
33. Johnson BD et al. (2004) Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109: 2993-2999
34. Sandstede JJ et al. (2004) Time course of 23Na signal intensity after myocardial infarction in humans. Magn Reson Med 52: 545-551
35. Selvanayagam JB et al. (2004) Value of delayedenhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 110: 1535-1541
36. Elliott MD and Kim RJ (2005) Late gadolinium cardiovascular magnetic resonance in the assessment of myocardial viability. Coron Artery Dis 16: 365-372
37. Conway MA et al. (1991) Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338: 973-976
38. Conway MA et al. (1998) Mitral regurgitation: Impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation 97: 1716-1723
39. Beyerbacht HP et al. (2001) Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function. Radiology 219: 637-643
40. Scheuermann-Freestone M et al. (2003) Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107: 3040-3046
41. Diamant M et al. (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42 328-335
42. Metzler B et al. (2002) Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J Cardiovasc Magn Reson 4: 493-502
43. Robinson M et al. (2006) Abnormal cardiac energetics are associated with diastolic dysfunction in uncomplicated obesity. Circulation 18: 905